WO1995020391A1 - Onguent oleagineux a base de prostacycline - Google Patents
Onguent oleagineux a base de prostacycline Download PDFInfo
- Publication number
- WO1995020391A1 WO1995020391A1 PCT/JP1995/000106 JP9500106W WO9520391A1 WO 1995020391 A1 WO1995020391 A1 WO 1995020391A1 JP 9500106 W JP9500106 W JP 9500106W WO 9520391 A1 WO9520391 A1 WO 9520391A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- methyl
- prostaglandin
- dimethyl
- methanol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Definitions
- the present invention relates to a composition for skin application, which has excellent pharmacological effects, and particularly an oil-based ointment containing prosucylcycline, which contains prosucylcycline as an active ingredient.
- Antibacterial agents for the purpose of sterilization, enzyme preparations for the digestion of tissues, skin cleaning fluid or water-absorbent polymer powder, wound dressings, etc. are used as therapeutic agents for various skin ulcers such as pressure ulcers and burns. ing.
- prostaglandins which have peripheral circulatory action, platelet aggregation inhibitory action or vasodilatory action, as transdermal preparations to these skin ulcers as drugs with a new mechanism of action.
- Skin preparations include semi-solid preparations (ointments, creams), patches, lotions, etc.
- semi-solid preparations ointments, creams
- patches for skin ulcer sites due to peripheral circulatory insufficiency or sites that may become skin ulcers Ointment with less irritation, especially oily ointment, is preferred.
- Prostaglandins and other oily softeners are reported in Japanese Patent Application Laid-Open No. 424,827.
- the compound of the formula (I) and its isomer are used as an external preparation, this compound is compared with, for example, the compound described in Japanese Patent Application Laid-Open No. 424,827, and is referred to as a prostaglandin nomenclature.
- Those in which the 16-position and 17-position are not substituted with an alkyl group are susceptible to oxidation of the 15-position hydroxyl group, and have a shorter life in vivo.
- the compound represented by the above formula (I) is said to have extremely high activity, a short life span in vivo, and few systemic side effects, which are general properties of prostaglandins. It has activity similar to evening code (local hormone).
- Japanese Patent Application Laid-Open No. 4-2438727 discloses an example of an oily ointment having good stability! :
- this publication does not describe the duration of the drug effect at all, and in fact, even if an external preparation of proscine cyclins represented by the formula (I) is prepared according to the method of the Examples, Control of sustained efficacy and release is not possible.
- an object of the present invention is to use proscine cyclins as an external preparation, which has excellent percutaneous absorbability so that it can be safely used for skin it diseases regardless of the presence or absence of keratin.
- Another object of the present invention is to provide a preparation in which the release of the base drug from the base is controlled.
- the inventors of the present invention have conducted intensive studies to solve the above-mentioned problems, and as a result, by using petrolatum, an appropriate amount of paraffin and a solubilizing agent, the release of the main drug from the ointment was achieved. C and successfully obtained an oily ointment with good transdermal absorption and long-lasting properties. C. Add an appropriate amount of glycol to petrolatum. As a result, the present inventors have found that an excellent release controlling effect can be obtained, and have found an oil-based ointment excellent in percutaneous absorbability and sustained efficacy of the prostaglandins represented by the formula (I). Reached.
- R 1 is a hydrogen atom, ⁇ C].
- R 2 represents R 21 or (CH 2 ) R 22 (where R 21 is an optionally substituted C 3 -C! 2 linear or branched alkyl group) A branched alkyl group, an alkenyl group or an alkynyl group, R 22 represents a cycloalkyl group of optionally substituted C 3 -C], n represents an integer of 0 to 2, 3 and R 4 are each independently a hydrogen atom or a formula (E) -C-R 5
- R 5 is C, Table to a linear or branched alkyl group -C 5.
- the mixture contains proscine cyclins and / or their enantiomers, and, in the first aspect of the present invention, celluloses, paraffins and fatty acid esters, and if necessary, liquid paraffin.
- a prosthetic cyclin-containing skin-care application composition comprising:
- the present invention comprises the above-mentioned prosyl cyclins and Z or an enantiomer thereof, petrolatums and glycols, and if necessary, paraffins and Z or liquid paraffin.
- FIG. 1 is a graph showing the results of a release test of a main drug from the preparation of the present invention
- FIG. 2 is a graph showing the results of a release test of the active drug from the formulation of the present invention
- FIG. 3 is a graph showing the results of a release test of the active drug from the formulation of the present invention
- FIG. 4 is a graph showing the results of a test on skin blood flow in topical application of the preparation of the present invention.
- FIG. 5 is a graph showing the results of a test on skin blood flow in topical application of the present invention.
- FIG. 6 is a graph showing the results of a test on skin blood flow in topical application of the preparation of the present invention.
- FIG. 7 is a graph showing the results of a test on skin blood flow in topical application of the preparation of the present invention.
- R ′ represents a hydrogen atom, a straight-chain or branched alkyl group of C, to (:,., And an alkyl group of C, to C, for example, methyl Group, ethyl group, n-propyl group, isopropyl group, n-butyl group, sec-butyl group, tert-butyl group, n-pentyl group, n-hexyl group, n-heptyl group, n- Okuchiru group, n- nonyl group, among can and Ageruko things like n- decyl group C, alkyl group -C 6, particularly d ⁇ (:.. arbitrary preferred alkyl groups 4 as R 1 is , A hydrogen atom and a methyl group are preferred, and a methyl group is particularly preferred.
- R 2 represents R 21 or (CH 2 ) n R 22 (where R 21 is an optionally substituted C 3 -C, 2 linear or branched alkyl group) Represents an alkenyl group or an alkynyl group, R 22 represents an optionally substituted C 3 -C, cycloalkyl group, and n represents an integer of 0 to 2).
- R 21 is an optionally substituted C 3 -C, 2 linear or branched alkyl group
- R 22 represents an optionally substituted C 3 -C, cycloalkyl group
- n represents an integer of 0 to 2 2).
- Examples of the unsubstituted C 3 -C 12 alkyl group for R 21 include n-propyl group, n-butyl group, n-pentyl group, 3-methylbutyl group, n-hexyl group, and 4-methylpentyl group.
- unsubstituted C 3 -C 12 alkenyl groups for R 21 include, for example, 3-butenyl group, 2-methyl-3-butenyl group, 3-pentenyl group, 2-methyl-3-pentenyl group, and 4-pentenyl group Group, 2-methyl-14-pentenyl group, 2,3-dimethyl-14-pentenyl group, 3-methyl-4-pentenyl group, 3-ethyl-2-methyl-14-pentenyl group, 3-hexenyl group, 4-Hexenyl group, 5-hexenyl group, 2-methyl-3-hexenyl group, 2-methyl-1-hexenyl group, 2-methyl-5-hexenyl group, 5-methyl-3-hexenyl , 5,5-dimethyl-hexenyl, 2,5-dimethyl-13-hexenyl, 2,3-dimethyl-4-hexenyl, 4-methyl-5-hexenyl, 2,4-dimethyl 5-hexenyl group, 4, 4-
- 6-nonenyl group 2,3-dimethyl-6-nonenyl group, 4-methyl- 6-nonenyl group, 2,4—dimethyl-1-6-nonenyl group, 4,4—dimethyl-6-nonenyl group, 2,4,4-trimethyl-1-nonenyl group, 5-methyl-6-nonenyl group, 2,5-dimethyl-6-nonenyl group, 8-methyl-16-nonenyl group, 2 , 8-Dimethyl-1-6-nonenyl group, 8,8-Dimethyl-1-6-nonenyl group, 2,8,8-Trimethyl-6-nonenyl group, 3-Methyl-5-nonenyl group, 2 , 3-Dimethyl-5-nonenyl group, 3,3—Dimethyl-5-nonenyl group, 2,3,3-trimethyl-5-nonenyl group, 4-methyl-5-nonenyl group, 2,4-1 Dimethyl-5-nonenyl group, 4,4—
- 6-noninyl group 2,3-dimethyl-6-noninyl group, 4—methyl-1-6-noninyl group, 2,4-dimethyl-6-noninyl group, 4,4-dimethyl-6-noninyl group, 2,4, 4-trimethyl-6-noninyl group, 5-methyl-6-noninyl group, 2,5-dimethyl-6-noninyl group, 8-methyl-6-noninyl group, 2,8-dimethyl-6-noninyl group, 8,8-dimethyl-6-noninyl group, 2,8,8-trimethyl-6-noninyl group, 3-methyl-5-noninyl group, 2,3—dimethyl-15-noninyl group, 3,3—dimethyl-1-5 —Noninyl, 2,3,3-trimethyl-5-noninyl, 4-methyl-5-noninyl, 2,4—dimethyl-15-noninyl, 4,4-dimethyl-15-noniny
- off Tsu-containing, halogen atom such as chlorine: main butoxy group, e butoxy group, Purobokishi group, low-grade alkoxy group and butoxy group: cyclopentyl, to consequent opening hexyl group, etc.
- C 8 cycloalkyl groups Of these, a lower alkoxy group and a cycloalkyl group are preferred.
- R 21 preferably represents a C 3 to C 7 linear or branched alkyl group.
- Examples of the C 3 -C 7 alkyl group include n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, 2-methylhexyl, and 2-methyl Examples include a pentyl group and the like.
- R 22 in the formula (I) represents (CH 2 ) n R 22
- R 22 may be substituted C 3 to C! .
- cyclopentyl group and cyclohexyl group are mentioned cyclohexylene, among others Shikuroa alkyl group of C 3 -C 8, correct particularly preferred cycloalkyl group C 4 -C 7 .
- substituents examples include a lower alkyl group of C 6 to C 6 such as a methyl group, an ethyl group, a propyl group, and a hexyl group; Fluorine atom: lower alkoxy group such as methoxy group, ethoxy group, propoxy group, butoxy group; halogenated lower alkyl group such as trifluoromethyl group;
- n represents an integer of 0 to 2.
- R 3 and R 4 are each independently, that is, the same or different, and a hydrogen atom or a formula (I):
- R 5 represents a C 1, to C 5 linear or branched alkyl group, and specific examples thereof are the same as those of R 2 ).
- R 5 an alkyl group of C, to (: 3 is preferable, and among them, a linear group is preferable.
- R 5 a methyl group is particularly preferable.
- R 3 and R 4 hydrogen is particularly preferable.
- the prostacyclin represented by the formula (I) has a configuration at the 8-, 9-, 11-, 12-, and 15-positions that is different from that of natural proscyclin. Although they are the same and are particularly useful stereoisomers, the present invention includes a stereoisomer resulting from the difference in the configuration at each position, or a mixture thereof in any ratio.
- Preferred specific examples of the proscine cyclins used in the present invention are as follows, for example.
- the proscine cyclins represented by the formula (I) can be easily produced by a known method.
- the production method is described in detail in, for example, JP-A-59-210444 and JP-A-6-197518.
- the concentration of the broth cyclin relative to the total amount of the ointment may be any amount as long as it has a therapeutic effect, and is, for example, in the range of 0.001% by weight to 0.1% by weight. Can be A preferred range is from 0.001% to 0.01% by weight.
- Examples of the serine used in the composition of the present invention composed of the main drug, acerine, paraffins, and a fatty acid ester include white acerin and yellow acerine, with white acerine being preferred.
- the paraffins in the present invention mean paraffins or barraffinx.
- White petrolatum is preferably 80 to 100 weight by weight. Paraffins are preferably in the range of 1 to 25% by weight of the total amount, and particularly preferably in the range of 3 to 15% by weight, in which remarkable improvement in drug efficacy is observed. Further considering the consistency, the range of 3 to 10% by weight is most preferable.
- fatty acid esters examples include diisopropyl isopropyl adipate, isopropyl palmitate, isopropyl myristate, etc., which are solubilizers of the main drug and are combined with paraffins. Controls transdermal absorption. These fatty acid esters are ointments It can be added in a range of less than 1% by weight of the total amount of the agent, preferably in a range of 0.5% by weight or less.
- petrolatum used as petrolatum is preferably white petrolatum.
- Paraffin and / or liquid paraffin can be added to adjust the consistency of the ointment.
- Glycols play a role in controlling the release of the active ingredient from the ointment base, for example, ethylene glycol.
- propylene glycol 1,3-butanediol
- polyethylene glycol 200, 300, and 400 preferred are propylene glycol, 1,3-butanediol, polyethylene glycol 200, 300, and 400.
- the amount of glycols added is preferably in the range of 0.01 to 10% by weight of the total amount from the viewpoint of the sustained efficacy of the drug, and especially 0.1 to 5% by weight, in which remarkable sustained efficacy is observed. Range is preferred.
- active ingredients in addition to the above bases, active ingredients, transdermal absorption regulators and solubilizers, if necessary, paraoxybenzoic acid esters, benzoic acid, sodium benzoate, salicylic acid, sorbic acid, potassium sorbate And preservatives such as phosphoric acid; antioxidants such as butylhydroxyanisole and butylhydroxyl'toluene; surfactants, humectants, thickeners, fragrances, and colors Ointments can be appropriately added as long as the effects of the present invention are not impaired, and ointments can be produced by a usual method. For example, prostacyclin is added to a solubilizer and dissolved. This solution may be separately added to a heated and melted ointment base, a transdermal absorption modifier or other mixture of additives, and then uniformly mixed and cooled.
- composition containing prostazyclines may be used for skin ulcers, for example, pressure ulcers, burn ulcers, vascular ulcers, diabetic ulcers, peripheral circulatory disorders, ulcers associated with collagen diseases, and other ulcers and vibration diseases, Bajaja disease C) and can be used as a therapeutic agent for peripheral circulatory dysfunction such as Reino's disease.
- the composition containing prostazacyclines of the present invention did not show any particularly problematic toxicity.
- the ointment of the present invention showed not only a favorable increase in skin blood flow in the skin blood flow test described below, but also a clear sustained efficacy. This proves that prosthetic cyclins, the main drug, are more rapidly and continuously absorbed from the applied skin site than the ointment formulation of the present invention, and exhibit a long-term effect. Yes, it is an exceptional formulation.
- a softener was obtained in the same manner as in Example 1 except that propylene glycol was replaced with triethylene glycol.
- Example 8-An ointment was obtained in the same manner as in Example 1 except that propylene glycol was replaced with polyethylene glycol.
- Example 2 The propylene glycol of Example 2 was converted to diisopropyl adipate Instead, an ointment was obtained in the same manner.
- a softening agent was obtained in the same manner as in Example 1 except that propylene glycol was replaced with 1-propanol.
- a release test of the main drug from the base was carried out. 7 Omg of the ointment obtained in Examples and Comparative Examples was uniformly applied on a glass surface of 10 cm 2 and immersed in a 40% aqueous ethanol solution (reservoir solution). A part of this solution was collected over time, and the main drug in the solution was quantified by liquid chromatography.
- the amount of main drug released into the reservoir solution relative to the amount of main drug in the applied ointment was defined as the release rate.
- the results are shown in FIGS. 1, 2 and 3.
- the vertical axis represents the release rate, and the horizontal axis represents the time elapsed since the application of the composition.
- Release rate () (main drug amount in reservoir solution Z main drug amount in applied ointment) X 10 0
- the skin blood flow at the administration site was measured.
- 23 mg of each of the compositions obtained in the Examples and Comparative Examples was applied unsealed to 1 cmxlcm on the thigh of a hairless rat anesthetized with urethane.
- the skin blood flow at the administration site was measured with a laser Doppler blood flow meter.
- a difference between before and after the application of the ointment was obtained as a blood flow increase value.
- the results are shown in FIG. 4, FIG. 5, FIG. 6, and FIG.
- the vertical axis indicates the difference in blood flow before and after application of the composition as a blood flow increase value
- the horizontal axis indicates the time elapsed since the application of the composition.
- a sustained release from the ointment of the main drug was observed in the release test, and not only a marked increase in skin blood flow was observed in the skin blood flow test, but also was observed.
- the ointment base of the present invention is useful for converting prostazacyclins of the formula (I) having high activity and short life span in vivo into ulcerative skin diseases and skin diseases which may cause ulcerative skin diseases. It is an excellent ointment with long-lasting efficacy, stability of the active ingredient, and low irritation to the skin, such as ulcerative dermatosis, burja disease, etc. Is expected to be used as a therapeutic agent for peripheral circulatory insufficiency o
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95906535A EP0693284A4 (en) | 1994-01-28 | 1995-01-27 | PROSTACYCLIN CONTAINING OILY OINTMENT |
KR1019950704102A KR960700725A (ko) | 1994-01-28 | 1995-01-27 | 프로스타시클린- 함유 유지성 연고제(prostacyclin-contatning oleaginous ointment) |
AU14672/95A AU1467295A (en) | 1994-01-28 | 1995-01-27 | Prostacyclin-containing oleaginous ointment |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6/8892 | 1994-01-28 | ||
JP889294 | 1994-01-28 | ||
JP6/19258 | 1994-02-16 | ||
JP1925894 | 1994-02-16 | ||
JP6/180093 | 1994-08-01 | ||
JP06180093A JP3115483B2 (ja) | 1994-02-16 | 1994-08-01 | プロスタサイクリン類含有皮膚適用組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995020391A1 true WO1995020391A1 (fr) | 1995-08-03 |
Family
ID=27278226
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1995/000106 WO1995020391A1 (fr) | 1994-01-28 | 1995-01-27 | Onguent oleagineux a base de prostacycline |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0693284A4 (ja) |
KR (1) | KR960700725A (ja) |
AU (1) | AU1467295A (ja) |
CA (1) | CA2159224A1 (ja) |
WO (1) | WO1995020391A1 (ja) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59128327A (ja) * | 1983-01-10 | 1984-07-24 | Teijin Ltd | 7−チアプロスタグランジンe↓1類を有効成分とする経皮投与用薬剤 |
JPS63135333A (ja) * | 1986-11-26 | 1988-06-07 | Nitto Electric Ind Co Ltd | プロスタグランジン類含有貼付剤 |
JPH02207018A (ja) * | 1989-02-07 | 1990-08-16 | Kao Corp | 皮膚外用剤 |
JPH04243827A (ja) * | 1991-01-25 | 1992-08-31 | Sumitomo Pharmaceut Co Ltd | プロスタグランジン誘導体含有溶解型軟膏剤 |
WO1994017805A1 (en) * | 1993-02-03 | 1994-08-18 | Teijin Limited | Dermatologic preparation composition containing isocarbacyclin as active ingredient |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0634172A4 (en) * | 1993-02-03 | 1995-08-02 | Teijin Ltd | COMPOSITION FOR DERMATOLOGICAL PREPARATION CONTAINING PROSTACYCLINE AS ACTIVE INGREDIENT. |
-
1995
- 1995-01-27 CA CA002159224A patent/CA2159224A1/en not_active Abandoned
- 1995-01-27 KR KR1019950704102A patent/KR960700725A/ko not_active Application Discontinuation
- 1995-01-27 AU AU14672/95A patent/AU1467295A/en not_active Abandoned
- 1995-01-27 EP EP95906535A patent/EP0693284A4/en not_active Withdrawn
- 1995-01-27 WO PCT/JP1995/000106 patent/WO1995020391A1/ja not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59128327A (ja) * | 1983-01-10 | 1984-07-24 | Teijin Ltd | 7−チアプロスタグランジンe↓1類を有効成分とする経皮投与用薬剤 |
JPS63135333A (ja) * | 1986-11-26 | 1988-06-07 | Nitto Electric Ind Co Ltd | プロスタグランジン類含有貼付剤 |
JPH02207018A (ja) * | 1989-02-07 | 1990-08-16 | Kao Corp | 皮膚外用剤 |
JPH04243827A (ja) * | 1991-01-25 | 1992-08-31 | Sumitomo Pharmaceut Co Ltd | プロスタグランジン誘導体含有溶解型軟膏剤 |
WO1994017805A1 (en) * | 1993-02-03 | 1994-08-18 | Teijin Limited | Dermatologic preparation composition containing isocarbacyclin as active ingredient |
Non-Patent Citations (1)
Title |
---|
See also references of EP0693284A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP0693284A1 (en) | 1996-01-24 |
CA2159224A1 (en) | 1995-08-03 |
KR960700725A (ko) | 1996-02-24 |
AU1467295A (en) | 1995-08-15 |
EP0693284A4 (en) | 1996-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR0167613B1 (ko) | 사이클로스포린-함유 연질캅셀제 조성물 | |
KR950002878B1 (ko) | 피부외용 크리임제제 | |
JP5938497B2 (ja) | 抗真菌医薬組成物 | |
JP2853902B2 (ja) | プロスタサイクリン類を活性成分として含有する外用皮膚血流量増加剤 | |
JP2923503B2 (ja) | 軟質ゼラチンカプセル剤 | |
US5612327A (en) | 1α,24-(OH)2 -cholecalciferol emulsion composition and method for treating psoriasis | |
HU206110B (en) | Process for producing azelatine salts with improved solubility and pharmaceutical compositions comprising same | |
JPS61118315A (ja) | ステロイド−17−モノエステル含有クリ−ム剤 | |
US4344940A (en) | Steroid formulation containing dipotassium EDTA | |
EP0746318A1 (en) | Injectable emulsions containing antifungal triazole derivatives | |
US5196417A (en) | Piroxicam-containing pharmaceutical composition for topical use | |
WO1995020391A1 (fr) | Onguent oleagineux a base de prostacycline | |
JPH0361644B2 (ja) | ||
WO1994017806A1 (en) | Dermatologic preparation composition containing prostacyclin as active ingredient | |
JP3115483B2 (ja) | プロスタサイクリン類含有皮膚適用組成物 | |
JP3115482B2 (ja) | プロスタサイクリン類含有皮膚適用組成物 | |
WO1994017805A1 (en) | Dermatologic preparation composition containing isocarbacyclin as active ingredient | |
WO1994017804A1 (en) | Pharmaceutical composition for treating cerebral thrombosis | |
JP4101464B2 (ja) | 抗炎症軟膏剤 | |
JP2700990B2 (ja) | 経皮吸収促進物質及び皮膚外用剤組成物 | |
EP3192515B1 (de) | Pharmazeutische zusammensetzung enthaltend 7beta-hydroxycholesterol geeignet zur intravenösen verabreichung | |
JPH0251403B2 (ja) | ||
WO1995033465A1 (fr) | Composition pharmaceutique pour le traitement de troubles du systeme circulatoire peripherique | |
KR20000075940A (ko) | 제약 조성물 | |
BE1015784A6 (fr) | Creme dermique. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2159224 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 1995 530248 Country of ref document: US Date of ref document: 19950928 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995906535 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1995906535 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995906535 Country of ref document: EP |